Bayer AG

AskBio Completes AB-1002 Phase II Clinical Trial Participant Enrollment

DKSH and Bayer Thailand Expand Partnership for Endometriosis Drug Commercialization

Bayer and Charite Hospital Collaborate to Establish Berlin Health Innovation Zone

Inclusive Capital Partners Plans to Sell Bayer Shares

Bayer Obtains Approval for Low-dose MRI Contrast Agent in Japan

UBS Raises Bayer's Rating to 'Buy' with a Target Price of €52

Bayer Projects 2026 Revenue of 45-47 Billion Euros

Bayer Announces Significant Efficacy in PEACE-3 Clinical Trial

UBS Raises Bayer's Target Price to 48 Euros

Monsanto Reaches Roundup™ Class Settlement Agreement

Goldman Sachs Reduces Voting Rights in Bayer (ADR) to 5.27%

Bayer to Present asundexian Clinical Trial Results at International Stroke Conference

Bayer Receives Breakthrough Therapy Designation for Sevabernib from FDA and CDE

Goldman Sachs Raises Voting Rights in Bayer AG to 6.18%

Goldman Sachs Raises Its Voting Stake in Bayer AG

Bayer Launches Phase IIa Clinical Trial for Alport Syndrome Drug

Bayer Board Member Buys Shares Internally

Bayer Extends CEO Bill Anderson's Contract to March 31, 2029

Bayer's LYNKUET™ Receives Global Approval in the UK

Bayer Applies for EU Market Authorization for Gadoquatrane

BAYZF

LABU

BAYN

BAYRY

DZ BANK AG has upgraded Bayer (0P6S) to a Hold rating with a price target set by analyst Peter Spengler. This follows a similar Hold rating from TipRanks, while on the same day, another report downgraded Bayer to a Sell. Spengler is ranked #1675 among 12068 analysts according to TipRanks.

Tip Ranks

VanEck Biotech ETF

Bayer Aktiengesellschaft

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

iShares US Pharma

SPDR S&P Biotech

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Bayer

Invesco Biotechnology & Genome ETF

DZ BANK AG upgrades Bayer (0P6S) to a Hold

A progressive U.S. congresswoman and a leader of the MAHA movement are collaborating against Big Chemical, advocating for food free of toxic chemicals and accountability for corporations. They highlight the dangers of glyphosate, linking it to serious health issues and Bayer's substantial settlements. Their fight includes opposing a farm bill that would limit state pesticide regulations and a Supreme Court case that could affect legal claims against chemical manufacturers. This partnership underscores a growing political concern about food safety and corporate influence, resonating with voters across the political spectrum.

Thehill

Why a progressive and a MAHA activist are joining forces against Big Chemical

SBIO

Bayer Expects No Impact on FY26 Forecasts From New US Tariffs

marketscreener

ALPS Medical Breakthrough

iShares US Medical Devices

First Trust Indxx Global Agri

VanEck Agribusiness ETF

iShares MSCI Agriculture Producers ETF

iShares Global Healthcare

Health Care Select Sector SPDR

Invesco DB Agriculture FD ETF

VG Health

SPDR S&P Health Equip

Bayer Expects No Impact on FY26 Forecasts From New US Tariffs

Reuters

Bayer US head says tariffs will not affect its 2026 forecasts

Bayer's pharmaceuticals division aims for a 30% operating margin by 2030 and mid-single-digit revenue growth from 2027, focusing on innovation in China. The company is transitioning from older products to new assets, with significant declines in sales of key medicines like Xarelto and Eylea. Bayer emphasizes China's role as a biopharmaceutical innovation hub, enhancing partnerships and research capabilities. The company is also integrating AI to improve R&D productivity by 40% by 2030, while highlighting five key growth drivers for its business.

Yicai

Bayer Deepens China Innovation Bet as Pharma Unit Eyes 30% Margin

TEVA

LLYX

This week's biotech news highlights significant regulatory approvals, acquisitions, and clinical trial outcomes. ARS Pharma's Neffy nasal spray received FDA approval for broader use, while Novo Nordisk's Awiqli, a once-weekly insulin, gained FDA approval. Lupin and Teva also secured FDA approvals for generic and biosimilar products. Bayer expanded Kerendia's use in the EU, and GSK's Exdensur was approved in China. Eli Lilly announced its acquisition of Centessa Pharmaceuticals for approximately $6.3 billion in cash and contingent value rights.

rttnews

Teva Pharmaceutical Industries

Biogen

Direxion Daily LLY Bull 2X Shares

Invesco Nasdaq Biotechnology ETF

ARS Pharmaceuticals

Eli Lilly

Apellis Pharma

Centessa Pharmaceuticals

Novo Nordisk AS

Defiance Daily Target 2X Long NVO ETF

Defiance Daily Target 2X Long LLY ETF

Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS

Bayer has been asked to modify claims regarding its One A Day Men’s Pre-Conception Health Complete Multivitamin after a challenge from rival OLLY PBC. The BBB National Programs’ National Advertising Division found that Bayer's claims about boosting male fertility and the multivitamin's ingredients were unsupported. Bayer agreed to comply with the recommendations. This follows Bayer's recent marketing campaign featuring Ludacris and a consolidation of its consumer health division's work under Interpublic Group. Despite steady sales, the nutritionals segment saw a 4% decline in the latest earnings report.

Fiercepharma

Bayer rejigs marketing claims after advertising body challenge

UK Regulator OKs Bayer's Treatment for Advanced Non-small Cell Lung Cancer

UK Regulator OKs Bayer's Treatment for Advanced Non-small Cell Lung Cancer

UK's MHRA approves Bayer's sevabertinib to treat adults with HER2-positive lung cancer

UK's MHRA approves Bayer's sevabertinib to treat adults with HER2-positive lung cancer

Bayer in Talks with European Governments to Raise Drug Prices Amid US Curbs

Bayer in Talks with European Governments to Raise Drug Prices Amid US Curbs

Bayer has received approval from the European Commission for Kerendia (finerenone) in the EU, expanding its indication to treat adults with symptomatic chronic heart failure and left ventricular ejection fraction (LVEF) ≤40%. This approval follows positive results from the Phase III FINEARTS-HF study, broadening its use beyond patients with chronic kidney disease associated with type 2 diabetes. Bayer shares were last trading at 38.26 euros.

Bayer Announces Approval Of New Indication For Kerendia In The EU

EU Commissions OKs Expanded Indication for Bayer's Heart Failure Drug

EU Commissions OKs Expanded Indication for Bayer's Heart Failure Drug

Bayer AG(BAYN.DE)

Bayer AG Stock Performance Chart

DZ BANK AG upgrades Bayer (0P6S) to a Hold

Why a progressive and a MAHA activist are joining forces against Big Chemical

Bayer Expects No Impact on FY26 Forecasts From New US Tariffs

Bayer US head says tariffs will not affect its 2026 forecasts

Bayer Deepens China Innovation Bet as Pharma Unit Eyes 30% Margin